John Maraganore On The Orion-11 Phase 3 Results

John Maraganore on the ORION-11 Phase 3 Results

Alnylam Pharmaceuticals

AHA 2019: Results From The Phase 3 ORION-10 Trial — Prof R Scott Wright

Radcliffe Cardiology

A novel ADC, AZD5335, for the treatment of solid tumors

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

John Maraganore Speaks Out on His Role as Bio Chair

R. Scott Wright, MD: ORION-10 Findings

Final results from ATLANTIS cabozantinib arm for urothelial carcinoma

Effects of Renal Impairment and Inclisiran

Mayo Proceedings

Patients as the Center of the Drug Development Process

Twice a YEAR injection to treat high cholesterol | Breakthrough Trial

Pharmacist Formula

Founder Stories: John Maraganore, CEO of Alnylam pioneering RNAi therapeutics

Results from a genotype analysis of the ORION-9 trial in patients - Professor Derick Raal

EAS - The European Atherosclerosis Society

hATTR amyloidosis: Explore Genetic Testing

Alnylam Pharmaceuticals

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer

Grand Rounds in Urology

Aegon Q3 2015 Results

Alnylam Pipeline: Fitusiran and Inclisiran

Orgonite Healing Benefits & Properties | Energy Healing (Green Healing S3E53)

hATTR amyloidosis: Seek Family Support

Alnylam Pharmaceuticals

Dr. John Maraganore, CEO of Alnylam Pharma, Discusses Henri Termeer

MCP 60 Seconds With Dr R. Scott Wright on Inclisiran

Mayo Proceedings